← All Wire coverage

Situationmaterial

FDA approves Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type ...

Carried more widely than almost anything else in the last 30 days

Reports

18

Domains carrying it

17

First reported

28 August 2026

Latest report

1 September 2026

Sectors

Health

Where

United States

Timeline

  1. 28 August 2026FDA approves Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type ...investor.lilly.com
  2. 29 August 2026Lilly joins Novo in cardiovascular space after FDA nod for GLP-1/GIP agonist Mounjarobiospace.com
  3. 30 August 2026Mounjaro Approved for Heart Attack, Stroke Risk Reduction in Diabeteschosun.com
  4. 31 August 2026Eli Lilly gets green light to market Mounjaro for heart attacks and strokes in the USmedwatch.com
  5. 1 September 2026Does Mounjaro Reduce the Risk of Heart Attack + Stroke with Type 2 Diabetes? The FDA Says Yesbeyondtype1.org

Connected developments

Situations Wire finds semantically close to this one. Proximity, not cause.

Share

Wire has not analysed this situation yet

Below is every report Wire has gathered on this event, and the situations it connects to. The deeper analysis — why it happened, what changed, what would prove it wrong — is not written yet, so nothing here claims it.

Evidence

18 reports · 17 domains